New Drug for Mesothelioma
The drug is called Alimta, or pemetrexed disodium, and it's distributed by Eli Lilly and Company. Alimta is intended to be used along with cisplatin.
Only about 2,000 new cases of mesothelioma are diagnosed each year in the U.S. Patients live, on average, nine to thirteen months after diagnosis.
In a randomized clinical trial, patients receiving Alimta along with cisplatin lived an average of 12 months after the trial began, compared with nine months for those on cisplatin alone.
Alimta must be supplemented with vitamin B-12 and folic acid to decrease the incidence and severity of adverse effects.
Those effects include low white blood count, nausea, vomiting, fatigue, rash and diarrhea. Since the drug suppresses the bone marrow, patients are warned to report signs of infection, such as fever and chills
From FDA (USA)
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
n.p. "New Drug for Mesothelioma." Medical News Today. MediLexicon, Intl., 21 Apr. 2004. Web.
25 Jun. 2017. <http://www.medicalnewstoday.com/releases/7499.php>
n.p. (2004, April 21). "New Drug for Mesothelioma." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.